IAPP and type 2 diabetes mellitus: Pramlintide at doses of 30 and 60 mcg in patients with type 1 diabetes and at a dose of 120 mcg in patients with type 2 diabetes has been shown to result in plasma pramlintide concentrations that approximate physiological postprandial plasma amylin concentrations in healthy subjects [8].